Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      FDA Approves Long-acting Injectable for Bipolar Disorder

      FDA Approves Long-acting Injectable for Bipolar Disorder

      Ruby Khatun Khatun5 Aug 2017 9:20 AM IST
      Valby, Denmark and Tokyo, Japan: Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced Abilify Maintena®(aripiprazole) for...
      Lupin gets USFDA nod for cholesterol-lowering drug

      Lupin gets USFDA nod for cholesterol-lowering drug

      Ruby Khatun Khatun5 Aug 2017 9:18 AM IST
      New Delhi: Drug firm Lupin on Thursday said it has received final approval from the US health regulator to market its Rosuvastatin Calcium tablets...
      Biocon Q1 net profit slumps 51 percent to Rs 81 crore

      Biocon Q1 net profit slumps 51 percent to Rs 81 crore

      Ruby Khatun Khatun5 Aug 2017 9:16 AM IST
      New Delhi: Bio-pharmaceutical firm Biocon reported a 51.20 per cent decline in its consolidated net profit to Rs 81.3 crore for the quarter ended...
      AstraZeneca gets breakthrough status for blood cancer drug

      AstraZeneca gets breakthrough status for blood cancer drug

      Ruby Khatun Khatun5 Aug 2017 9:15 AM IST
      LONDON: AstraZeneca said that U.S. regulators had awarded its blood cancer drug acalabrutinib "breakthrough" status for the treatment of patients with...
      Johnson & Johnson arthritis drug sirukumab raises safety concerns: FDA staff

      Johnson & Johnson arthritis drug sirukumab raises safety concerns: FDA staff

      Ruby Khatun Khatun5 Aug 2017 9:15 AM IST
      There were more deaths in patients taking Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab than among those taking a placebo,...
      Daiichi Sankyo settles US lawsuits over blood pressure drug Benicar

      Daiichi Sankyo settles US lawsuits over blood pressure drug Benicar

      Ruby Khatun Khatun5 Aug 2017 9:14 AM IST
      New York: Daiichi Sankyo on Tuesday said it has agreed to pay up to $300 million to settle some 2,300 U.S. cases accusing the Japanese drugmaker of...
      Cannot exceed 8 percent trade margin on Stents: NPPA

      Cannot exceed 8 percent trade margin on Stents: NPPA

      Ruby Khatun Khatun4 Aug 2017 6:00 PM IST
      New Delhi: NPPA has taken a step ahead to prevent distributors from grabbing higher profits and manipulating trade margins on coronary stents than the...
      FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia

      FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia

      Ruby Khatun Khatun4 Aug 2017 9:25 AM IST
      The U.S. Food and Drug Administration (FDA) approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid...
      USFDA gives final nod to Glenmark Pharma for anti-herpes drug

      USFDA gives final nod to Glenmark Pharma for anti-herpes drug

      Ruby Khatun Khatun4 Aug 2017 9:20 AM IST
      New Delhi: Glenmark Pharmaceuticals has received final approval from the US health regulator for Acyclovir Ointment used for treatment of herpes...
      Several Researches are ongoing for Developing New Drugs in AYUSH: Shri Shripad Naik

      Several Researches are ongoing for Developing New Drugs in AYUSH: Shri Shripad Naik

      Ruby Khatun Khatun4 Aug 2017 9:18 AM IST
      In an statement while giving written reply to a question in Lok Sabha, Minister of State (Independent Charge) for AYUSH, Shri Shripad Naik said...
      PNB ties up with Religare Health Insurance

      PNB ties up with Religare Health Insurance

      Ruby Khatun Khatun4 Aug 2017 9:16 AM IST
      Chennai: Religare Health Insurance announced its Bancassurance tie-up with one of the country's leading and largest banks – Punjab National Bank...
      Lupin first-quarter profit slumps, misses estimates

      Lupin first-quarter profit slumps, misses estimates

      Ruby Khatun Khatun4 Aug 2017 9:15 AM IST
      Drugmaker Lupin Ltd said on Wednesday first quarter profit fell 59 percent, well below analysts' estimates, as regulatory hurdles and pricing pressure...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok